aspect of
partnership)
→
CapableOf
→
continue to develop transmission-blocking vaccine
| Typicality: | 0.271 |
| Saliency: | 0.051 |
| partner → continue to develop → transmission-blocking vaccine | 4 |
| negative | neutral | positive |
| 0.037 | 0.788 | 0.175 |
| Raw frequency | 4 |
| Normalized frequency | 0.051 |
| Modifier score | 0.500 |
| Perplexity | 159.437 |